Vera Therapeutics (VERA) Projected to Post Earnings on Thursday

Vera Therapeutics (NASDAQ:VERA) will likely be announcing its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect the company to post earnings of ($1.62) per share and revenue of $3.42 million for the quarter. Parties can check the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:30 PM ET.

Vera Therapeutics (NASDAQ:VERA) last posted its quarterly earnings results on Monday, August 10th. The company reported ($1.52) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.58) by $0.06. During the same quarter last year, the business earned ($1.20) earnings per share. On average, analysts expect Vera Therapeutics to post ($6.45) EPS for the current fiscal year and ($4.55) EPS for the next fiscal year.

Vera Therapeutics Trading Down 2.4%

Vera Therapeutics stock opened at $30.25 on Tuesday. The business has a 50 day moving average price of $31.96 and a two-hundred day moving average price of $37.00. The company has a quick ratio of 10.92, a current ratio of 10.92 and a debt-to-equity ratio of 0.18. Vera Therapeutics has a 12 month low of $23.05 and a 12 month high of $56.05. The stock has a market cap of $2.18 billion, a price-to-earnings ratio of -5.16 and a beta of 1.06.

Insider Buying and Selling at Vera Therapeutics

In other news, CEO Marshall Fordyce sold 18,500 shares of the company’s stock in a transaction on Tuesday, September 15th. The stock was sold at an average price of $37.00, for a total transaction of $684,500.00. Following the transaction, the chief executive officer owned 235,244 shares of the company’s stock, valued at $8,704,028. This represents a 7.29% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 15.90% of the stock is currently owned by insiders.

Analysts Set New Price Targets

VERA has been the subject of a number of recent research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Vera Therapeutics in a report on Thursday, October 15th. JPMorgan Chase & Co. boosted their price target on Vera Therapeutics from $76.00 to $83.00 and gave the company an “overweight” rating in a research note on Tuesday, September 8th. TD Cowen reiterated a “buy” rating on shares of Vera Therapeutics in a research report on Tuesday, September 15th. Guggenheim upped their price target on Vera Therapeutics from $56.00 to $76.00 and gave the company a “buy” rating in a research report on Wednesday, July 8th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Vera Therapeutics in a research note on Friday, October 23rd. One analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Vera Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $76.86.

About Vera Therapeutics

Vera Therapeutics, Inc is a clinical-stage biotechnology company focused on developing treatments for immunological diseases. The company’s research is centered on therapies that target the underlying causes of autoimmune conditions rather than primarily addressing their symptoms.

Vera’s lead product candidate is atacicept, a biologic designed to inhibit the B-cell survival factors BLyS and APRIL. The company has been evaluating atacicept in IgA nephropathy, an autoimmune kidney disease that can lead to progressive loss of kidney function, and has also investigated its potential in other immune-mediated diseases.